References
- McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150(5):1051–4
- Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990; 99(3):805–10
- Norman JE, Beebe GW, Hoofnagle JH, et al. Mortality follow-up of the 1942 epidemic continued on page 68 hepatitis B in the U.S. Army. Hcpatology 1993; 18(4): 790–7
- Seef LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992: 327(27): 1906–11
- Koretz RL, Abbey H, Coleman E, et al. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 1993: 119(2):110–5
- Koretz RL. Acute hepatitis: science and superstition. In: Gitnick G, ed. Current hepatology. Vol 12. St Louis: Mosby-Year Book, 1992:1–51
- Deaths and hospitalizations from chronic liver disease and cirrhosis: United States, 1980–1989. MMWR 1993; 41 (52–53):969–73
- Wong JB, Koff RS, Tine F, et al. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122(9):664–75
- Koretz RL. Chronic hepatitis: more quotes and misquotes. In: Gitnick G, ed. Current hepatology. Vol 15. St Louis: Mosby-Year Book, 1995: 49–84
- Davis GL, Balart LA, Schilf ER, et al, for the Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989: 321(22): 1501–6
- Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferonalpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995: 346(8982): 1051–5